Mariusz Skwarczynski
Overview
Explore the profile of Mariusz Skwarczynski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
1945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skwarczynski M, Alharbi N, Nahar U, Shalash A, Azuar A, Koirala P, et al.
Bioorg Chem
. 2025 Feb;
157:108248.
PMID: 39952060
Immune stimulants (adjuvants) are essential vaccine components; however, clinically approved adjuvants are limited with the majority being derived from pathogenic components. In this study, the adjuvanting capacity of cholesterol, a...
2.
Zhao G, Sathkumara H, Miranda-Hernandez S, Seifert J, Valencia-Hernandez A, Puri M, et al.
Small
. 2025 Jan;
21(7):e2406874.
PMID: 39757706
After more than a century since its initial development, Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). Subunit boosters are considered a viable strategy to enhance BCG...
3.
Bojarska J, Wang X, Skwarczynski M
Front Pharmacol
. 2024 Dec;
15:1522148.
PMID: 39723250
No abstract available.
4.
Wang J, Bashiri S, Toth I, Skwarczynski M
Methods Mol Biol
. 2024 Jul;
2821:205-216.
PMID: 38997491
Enzyme-linked immunosorbent assay (ELISA) detects qualitatively and quantitatively the presence of antibodies or antigens in a sample. Due to its simplicity, high sensitivity, and user-friendliness, the test is widely used...
5.
Nahar U, Wang J, Shalash A, Lu L, Islam M, Alharbi N, et al.
Vaccine
. 2024 Jun;
42(23):126060.
PMID: 38897890
Subunit vaccines require an immunostimulant (adjuvant) and/or delivery system to induce immunity. However, currently, available adjuvants are either too dangerous in terms of side effects for human use (experimental adjuvants)...
6.
Zhao Z, Bashiri S, Ziora Z, Toth I, Skwarczynski M
Viruses
. 2024 May;
16(5).
PMID: 38793638
Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and fatalities worldwide. Extensive SARS-CoV-2 research has been...
7.
Lu L, Kong W, Zhang J, Firdaus F, Wells J, Stephenson R, et al.
Front Immunol
. 2024 Mar;
15:1298721.
PMID: 38469294
Subunit vaccines hold substantial promise in controlling infectious diseases, due to their superior safety profile, specific immunogenicity, simplified manufacturing processes, and well-defined chemical compositions. One of the most important end-targets...
8.
Koirala P, Shalash A, Chen S, Faruck M, Wang J, Hussein W, et al.
Vaccines (Basel)
. 2024 Feb;
12(2).
PMID: 38400181
Mucosal vaccines are highly attractive due to high patient compliance and their suitability for mass immunizations. However, all currently licensed mucosal vaccines are composed of attenuated/inactive whole microbes, which are...
9.
Alharbi N, Shalash A, Koirala P, C Boer J, Hussein W, Khalil Z, et al.
J Colloid Interface Sci
. 2024 Feb;
663:43-52.
PMID: 38387185
Peptide-based vaccines can trigger highly specific immune responses, although peptides alone are usually unable to confer strong humoral or cellular immunity. Consequently, peptide antigens are administered with immunostimulatory adjuvants, but...
10.
Jin S, Zhang J, Nahar U, Huang W, Alharbi N, Shalash A, et al.
ACS Infect Dis
. 2023 Jul;
9(8):1570-1581.
PMID: 37489053
Untreated group A (GAS) can lead to a range of life-threatening diseases, including rheumatic heart disease. To date, no therapeutic or prophylactic vaccines are commercially available to treat or prevent...